Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience
- 10 September 2007
- journal article
- Published by Wiley in BJU International
- Vol. 101 (2), 165-169
- https://doi.org/10.1111/j.1464-410x.2007.07190.x
Abstract
To examine the outcome of patients diagnosed with 'low-risk' prostate cancer managed by active surveillance (AS). In all, 157 men with localized prostate cancer were followed on AS. The inclusion criteria for AS included: Gleason score of < or = 6, a serum prostate-specific antigen (PSA) level of < or = 15 ng/mL, stage < or = T2, low-volume disease and > 12 months of follow-up. The follow-up was rigorous, with PSA tests and a digital rectal examination every 3 months for 2 years, and a repeat biopsy 6-12 months after the initial diagnosis and yearly when indicated. Continuance of AS was based on the PSA doubling time, re-biopsy score, Gleason score, tumour volume, stage progression and patient preference. In all 99 patients met the inclusion criteria; their mean age at diagnosis was 66 years, their mean PSA level 5.77 ng/mL and the mean follow-up 45.3 months. On initial repeat biopsy, 63% had no cancer and 34% had a Gleason sum of < or = 6. Eight patients were treated (three with hormones; five with curative intent); two had radical prostatectomy (one had pT2c pNO Gleason 7 disease); three had radiotherapy. The probability is that 85% would remain treatment-free at 5 years; no patient died from prostate cancer. The PSA doubling time and clinical stage at diagnosis were predictive of progression. Patients who are followed on AS must be selected using narrowly defined inclusion criteria and closely followed with a standard regimen of PSA testing, digital rectal examination and repeat biopsy.Keywords
This publication has 23 references indexed in Scilit:
- Defining High Risk Prostate Cancer—Where do we Set the Bar? A Translational Science Approach to Risk StratificationJournal of Urology, 2006
- Modeling Prostate Specific Antigen Kinetics in Patients on Active SurveillanceJournal of Urology, 2006
- Editorial CommentJournal of Urology, 2006
- Delayed versus immediate surgical intervention and prostate cancer outcome.JNCI Journal of the National Cancer Institute, 2006
- Active surveillance with selective delayed intervention for favorable risk prostate cancerUrologic Oncology: Seminars and Original Investigations, 2006
- Active Surveillance with Selective Delayed Intervention Using PSA Doubling Time for Good Risk Prostate CancerEuropean Urology, 2005
- Characteristics of insignificant clinical T1c prostate tumorsCancer, 2004
- LIMITATIONS OF BIOPSY GLEASON GRADE: IMPLICATIONS FOR COUNSELING PATIENTS WITH BIOPSY GLEASON SCORE 6 PROSTATE CANCERJournal of Urology, 2004
- Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes StudyCancer, 2003
- NONPALPABLE STAGE T1C PROSTATE CANCERJournal of Urology, 1998